Pfizer’s updated COVID shot effective against ‘Eris’ variant in mice study
(Reuters) – Pfizer Inc said on Thursday its updated COVID-19 shot, which is being tested against emerging variants, showed neutralizing activity against the “Eris” subvariant in a study conducted on mice. Pfizer,…
China Meheco to distribute Pfizer’s COVID treatment in China
HONG KONG (Reuters) – China Meheco Group Co Ltd said on Wednesday it signed an agreement with Pfizer Inc to import and distribute the U.S. drugmaker’s oral COVID-19 treatment Paxlovid in mainland…
Pfizer’s India arm posts profit jump on lower costs, price hikes
BENGALURU – Pfizer Ltd, the Indian arm of U.S. pharma giant Pfizer Inc, reported a rise in second-quarter profit on Friday, boosted by price hikes and lower input costs. Profit before tax…
U.S. government to test Pfizer’s Paxlovid for long COVID
By Julie Steenhuysen CHICAGO (Reuters) – The U.S. National Institutes of Health’s $1 billion RECOVER Initiative has picked Pfizer Inc’s antiviral drug Paxlovid as the first treatment it will study in patients…
U.S. doctors reconsider Pfizer’s Paxlovid for lower-risk COVID patients
By Deena Beasley (Reuters) – Use of Pfizer Inc’s COVID-19 antiviral Paxlovid spiked this week, but some doctors are reconsidering the pills for lower-risk patients after a U.S. public health agency warned…
U.S. CDC recommends re-isolation if COVID recurs after taking Pfizer’s pill
(Reuters) – Patients who experience recurrence of COVID-19 symptoms after completing treatment with Pfizer’s drug Paxlovid should isolate again for five days, the U.S. Centers for Disease Control and Prevention said in…
Evidence mounts for need to study Pfizer’s Paxlovid for long COVID – researchers say
By Julie Steenhuysen CHICAGO – Additional reports of patients with long COVID who were helped by Pfizer Inc’s oral antiviral treatment Paxlovid offer fresh impetus for conducting clinical trials to test the…
Pfizer’s vaccines head Kathrin Jansen to retire this year
(Reuters) – Pfizer Inc’s vaccines head Kathrin Jansen, who led the development of the U.S. drugmaker’s COVID-19 shot, has decided to retire later this year. “Over the last two years, Kathrin’s legendary…
The case for testing Pfizer’s Paxlovid for treating long COVID
By Julie Steenhuysen CHICAGO – Reports of two patients who found relief from long COVID after taking Pfizer Inc’s antiviral Paxlovid, including a researcher who tested it on herself, provide intriguing evidence…
Pfizer’s new CFO David Denton to get $1.25 million as annual base salary
(Reuters) – Pfizer Inc’s newly appointed chief financial officer, David Denton, will get $1.25 million as annual base salary, the pharmaceutical giant said in a regulatory filing on Tuesday. A similar amount…
Lawsuit over Pfizer’s disclosures before Chantix recall is dismissed
By Jonathan Stempel NEW YORK – A federal judge on Wednesday dismissed a proposed class action lawsuit by consumers who accused Pfizer Inc of failing to disclose the presence of cancer-causing agents…
Pfizer’s COVID cash pile opens opportunities for deals
By Manas Mishra – Investors on Tuesday hope to learn Pfizer Inc’s plans for what could be a once-in-a-generation cash infusion from COVID-19 treatments and vaccines in 2022, with some looking for…
Explainer-How does Merck’s COVID-19 pill compare to Pfizer’s?
By Deena Beasley – Rival antiviral pills from Pfizer Inc and Merck & Co that demonstrated efficacy in trials of adults with COVID-19 who are at high risk of serious illness are…
Breaking News
